Nerlynx Approved to Help Prevent Breast Cancer's Return

TUESDAY, July 18, 2017 — Nerlynx (neratinib) has been approved by the U.S. Food and Drug Administration to help prevent HER2-positive breast cancer from returning.
It’s the first drug designed to prevent return of HER2-positive breast cancer, a…
Source: Topamax